Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd has filed disclosures under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, concerning Hemal V Mehta and Sachin V Mehta. The filings, dated August 26, 2026, indicate the creation of a pledge on equity shares by individuals classified under the 'Promoter' category. This action pertains to the creation of pledge on equity shares of the company by persons belonging to the 'Promoter' category. The specific details of the pledge, including the number of shares and percentage, are provided in the enclosed disclosure documents.

Sudarshan Pharma Industries Ltd has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, concerning the creation of a pledge on equity shares by persons belonging to the 'Promoter' category. The disclosure, dated August 21, 2026, pertains to Hemal V Mehta and Sachin V Mehta. The filing indicates that 66,00,000 equity shares, representing 2.75% of the total paid-up capital, have been pledged. This action is part of the promoters' ongoing pledge activities, with a total of 66,00,000 shares currently pledged.

Sudarshan Pharma Industries Ltd announced the allotment of 48,11,730 fully paid-up equity shares following the conversion of Foreign Currency Convertible Bonds (FCCBs) worth USD 15,00,000. The allotment was approved by the FCCB Committee of the company on August 19, 2026. Each share has a face value of ₹1 and was issued at a price of ₹30.19, with a premium of ₹29.19 per share. This conversion increases the total issued and paid-up equity capital to ₹25,44,70,600, comprising 25,44,70,600 equity shares. The newly allotted shares are identical and rank pari-passu with existing equity shares.

Sudarshan Pharma Industries Ltd has filed a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing pertains to changes in the shareholding of the promoter group, Vasantrai Ratilal. Specific details of the shareholding changes, including acquisition or disposal of shares, are provided in the enclosed disclosure. The company has requested the BSE to take this information on record.

Sudarshan Pharma Industries Ltd has announced that its FCCB Committee will convene on Wednesday, August 19, 2026. The primary agenda for this meeting is to consider and approve the conversion of a portion of funds raised through FCCBs (Foreign Currency Convertible Bonds) into equity shares. The committee will also approve the allotment of these newly issued equity shares. This move is a step towards managing the company's debt structure and potentially increasing its equity base.

Sudarshan Pharma Industries Ltd has entered into a Memorandum of Understanding (MoU) to acquire 1,24,64,000 equity shares, representing 76% of the paid-up equity share capital, of a target company. The acquisition includes the target's business, manufacturing plant, and team, subject to due diligence and regulatory approvals. This move aims to achieve backward integration and establish end-to-end manufacturing capabilities for Sudarshan Pharma. The consideration involves cash and 40 lakh shares from Sudarshan Pharma's promoters. The target entity possesses accreditations from US FDA, WHO Geneva, and others, and has projected revenues for FY25-26. Upon completion, the target company will become a subsidiary of Sudarshan Pharma Industries Limited. The acquisition is expected to be completed by October 10, 2026.

Sudarshan Pharma Industries Ltd announced that its Board of Directors has approved the acquisition of 3,000 equity shares, representing 30.00% of the paid-up capital, in Sudarshan Maven Pharma Private Limited. The acquisition, valued at a cash consideration based on valuation, is expected to be completed by December 31, 2026. Upon completion, Sudarshan Maven, which is primarily engaged in pharmaceutical and healthcare products and has not yet commenced commercial activities, will become a wholly-owned subsidiary of Sudarshan Pharma. This move aligns with Sudarshan Pharma's existing business activities.

Sudarshan Pharma Industries Ltd announced its Board of Directors has approved the divestment of 2,09,100 equity shares, representing 51% of the paid-up share capital, in its subsidiary Ishwari Healthcare Private Limited. The transaction is expected to be completed by December 31, 2026. Following the divestment, Ishwari Healthcare will cease to be a subsidiary of Sudarshan Pharma. The exact consideration for the sale will be determined after a valuation of Ishwari Healthcare. The company is currently seeking a buyer for the stake at a competitive price.

Sudarshan Pharma Industries Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved the results along with the Auditors' Limited Review Report. The company's financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS). Sudarshan Pharma is engaged in the manufacturing of API, jobwork manufacturing in pharmaceuticals, and trading in chemicals and solvents, operating in a single reportable segment.

Sudarshan Pharma Industries Ltd has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, concerning the un-pledging of shares held by promoter Hemal Vasantrai Mehta. The filing, dated August 8, 2026, indicates a change in the shareholding status of the promoter. This action is a routine disclosure requirement under takeover regulations and may signal a shift in the promoter's financial arrangements or confidence in the company.